0000737207 true 0000737207 2021-05-05 2021-05-05 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

 

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

 

FORM 8-K/A

Amendment No. 1 

 

CURRENT REPORT

 

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

 

Date of Report (Date of Earliest Event Reported): May 5, 2021

 

Adhera Therapeutics, Inc.

(Exact name of registrant as specified in its charter)

 

Delaware   000-13789   11-2658569
(State or other jurisdiction   (Commission   (I.R.S. Employer
of incorporation)   File Number)   Identification No.)

 

8000 Innovation Parkway    
Baton Rouge, LA   70820
(Address of principal executive offices)   (Zip Code)

 

Registrant’s telephone number, including area code: 919-518-3748

 

Former name or former address, if changed since last report

 

Securities registered pursuant to Section 12(b) of the Act: None

 

Title of each class   Trading Symbol   Name of each exchange on which registered
—   —   —

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
   
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
   
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
   
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company ☐

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

 

 

 

 

EXPLANATORY NOTE

 

Adhera Therapeutics, Inc. filed a Current Report on Form 8-K on May 5, 2021 (the “Original Form 8-K”) to disclose the dismissal of the Company’s independent registered public accounting firm and the concurrent engagement of a new independent accounting firm.

 

This Amendment No. 1 filed on Form 8-K/A is being filed solely for the purpose of including as Exhibit 16.1 to this report the dismissed independent accounting firm, Baker Tilly, LLP, letter to the SEC dated May 11, 2021. This Amendment does not change any previously reported information or any disclosures contained in the Original Form 8-K.

 

Item 9.01 Financial Statements and Exhibits.

 

Exhibit No.   Description
     
16.1   Letter of Baker Tilly USA, LLP dated May 11, 2021

 

 

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

  ADHERA THERAPEUTICS, INC.
     
May 11, 2021 By: /s/ Andrew Kucharchuk
  Name: Andrew Kucharchuk
  Title: Chief Executive Officer

 

 

 

 

Adhera Therapeutics (PK) (USOTC:ATRX)
Gráfico Histórico do Ativo
De Mai 2024 até Jun 2024 Click aqui para mais gráficos Adhera Therapeutics (PK).
Adhera Therapeutics (PK) (USOTC:ATRX)
Gráfico Histórico do Ativo
De Jun 2023 até Jun 2024 Click aqui para mais gráficos Adhera Therapeutics (PK).